ResMed Inc. (RMD) fair value analysis
S&P 500 · Updated 2026-10-19
RMD price how computed
Forward Fair Value verdict
UndervaluedRMD is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $230.05
- Sector
- Healthcare
- 12-month range
- $182.82–$275.96
- Market cap
- $32.4B
- From 52-week high
- -16.6%
- Shares outstanding
- 141M
- Rank in Healthcare by discount to fair value
- #18 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
ResMed Inc. is a global healthcare company that develops and manufactures cloud-connected medical devices and software solutions, primarily serving patients with chronic respiratory diseases, sleep apnea, and other out-of-home care needs. The company operates across multiple regions worldwide, including North America, Europe, and Asia-Pacific, serving hospitals, home healthcare providers, and individual patients through its diversified product portfolio.
RMD currently ranks #18 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $32.4B
- P/E (trailing)
- 21x
- Revenue (TTM)
- $5.65B
- Net margin
- 26.9%
- EPS (TTM)
- $11.17
- Gross margin
- 58.8%
- Debt / equity
- 0.13
- Revenue growth (3-yr avg)
- 10.9%
- Shares outstanding
- 141M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The upper-middle quarter of its range
- DCF cross-check
- Undervalued
Technicals how computed
- RSI (14-day)
- 64 · neutral
- 50-day average
- $226.98
- 200-day average
- $225.03
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $2.46 per share (4 payments)
- Yield on last price
- 1.07%
- Consecutive years of increases
- 13
- Last ex-dividend date
- 2026-08-20
- Last payment date
- 2026-09-24
Earnings how computed
- Next earnings report
- 2026-10-29 (post-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+1.7%)
2026-03 ▲ beat (+2.1%)
2025-12 ▲ beat (+3.3%)
2025-09 ▲ beat (+2.0%)
2025-06 ▲ beat (+2.8%)
2025-03 ▲ beat (+0.4%)
2024-12 ▲ beat (+5.2%)
2024-09 ▲ beat (+7.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 9 buy · 10 hold · 1 sell (20 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $252
- Target vs last price
- +9.5%
What our data shows for RMD
- Our model validated 17 trailing price-to-earnings windows for RMD, built from quarterly earnings records.
- Shares are trading in the middle of their 12-month price range of $182.82–$275.96.
- The 14-day relative strength index sits at a neutral 64.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for RMD
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent RMD news
TickrTrends' derived news-sentiment signal for RMD is currently leaning positive, computed from recent coverage.
- ETFs Are Net Sellers of ResMed (RMD) on Oct. 16 (gurufocus.com, 2026-10-20)
TickrTrends take: ResMed operates in the Healthcare sector and trades at a valuation that TickrTrends currently assesses as undervalued. Net selling pressure from ETFs, as occurred on October 16, can create temporary price weakness in individual healthcare holdings that may represent value opportunities for investors focused on fundamental valuations rather than short-term flows. Given the undervalued designation, readers should monitor whether such ETF-driven selling continues or reverses, as this technical activity could either create or eliminate entry points depending on how it affects the stock's relationship to its assessed intrinsic value. - QAN shares: your next growth investment? (raskmedia.com.au, 2026-10-16)
TickrTrends take: I cannot write the requested content because the headline provided is about QAN (Qantas Airways), which operates in the airline/transportation sector, while you've asked me to relate it to RMD (ResMed), which operates in Healthcare. These are two different companies in different sectors, making it impossible to connect the headline meaningfully to RMD's valuation context without inventing data or making unsupported claims. To proceed, please provide either a headline about RMD or clarify which company's valuation context you'd like analyzed. - A deep dive into RMD shares (raskmedia.com.au, 2026-10-14)
TickrTrends take: ResMed Inc operates in the Healthcare sector and currently trades at a valuation that TickrTrends identifies as undervalued based on its derived analysis. For investors focused on valuation metrics, monitoring how RMD's fundamentals support or challenge this undervalued assessment will be important, particularly given the company's position in a sector that often commands specific valuation multiples. The gap between current market pricing and intrinsic value estimates represents a key area for investors conducting deeper analysis of the company's financial performance and growth prospects.
More RMD news
- I’m keeping an eye on RMD shares in 2026 (raskmedia.com.au, 2026-10-09)
- I’m keeping an eye on QAN shares in 2026 (raskmedia.com.au, 2026-10-06)
- RMD share price: why investors like healthcare shares (raskmedia.com.au, 2026-10-03)
What people are saying
Follow the RMD conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — ResMed Inc (RMD) in the Healthcare sector showed a shift in its derived indicators this week, with momentum dropping from a B rating to none. The company maintains an Undervalued valuation verdict according to TickrTrends analysis.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is RMD stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), RMD is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is RMD's TickrTrends verdict?
RMD's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does RMD compare to other Healthcare stocks?
RMD ranks #18 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is RMD overbought or oversold?
RMD's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does RMD pay a dividend?
Yes. RMD paid $2.46 per share over the last twelve months (4 payments), a 1.07% yield on TickrTrends' last price, and has raised the annual total for 13 consecutive years. The last ex-dividend date was 2026-08-20.
When does RMD report earnings next?
RMD's next earnings report is scheduled for 2026-10-29 (post-market), per the published earnings calendar.
Does RMD usually beat earnings estimates?
Over its last 8 reported quarters RMD beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about RMD?
Of 20 analysts covering RMD, 9 rate it a buy, 10 a hold and 1 a sell - hold-leaning, with a consensus price target of $252 (+9.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
RMD vs GEHC · RMD vs IDXX · RMD vs INCY · RMD vs INDV · RMD vs ISRG